You are here
Principia Biopharma Appoints John W. Smither to Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran John W. Smither, Chief Financial Officer of Sienna Biopharmaceuticals, Inc., to its Board of Directors and as chairperson of its Audit Committee. Mr. Smither currently serves as a board member and chair of the Audit Committee for both Achaogen, Inc. and eFFECTOR Therapeutics, Inc.
Tuesday, February 19, 2019 - 16:10